Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics
| Autor: | Aurélie Delacrétaz, Céline Dubath, Laurent Holzer, Anne-Emmanuelle Ambresin, Frederik Vandenberghe, Mehdi Gholam-Rezaee, Anaïs Glatard, Philippe Conus, Chin B. Eap, Axel Levier |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Longitudinal study Adolescent Antidepressive Agents/adverse effects Antidepressive Agents/therapeutic use Antipsychotic Agents/adverse effects Antipsychotic Agents/therapeutic use Cholesterol/blood Disease Progression Female Follow-Up Studies Humans Hypercholesterolemia/blood Hypercholesterolemia/chemically induced Lipids/blood Longitudinal Studies Mental Disorders/blood Mental Disorders/drug therapy Triglycerides/blood Young Adult Hypercholesterolemia chemistry.chemical_compound Interquartile range Internal medicine medicine Bipolar disorder Young adult Triglycerides Cholesterol Mental Disorders medicine.disease Lipids Antidepressive Agents Psychiatry and Mental health chemistry lipids (amino acids peptides and proteins) medicine.symptom Weight gain Dyslipidemia Antipsychotic Agents Lipoprotein |
| Zdroj: | The Journal of clinical psychiatry, vol. 80, no. 3 |
| ISSN: | 1555-2101 |
| DOI: | 10.4088/jcp.18m12414 |
| Popis: | Lipid disturbances following treatment with second-generation antipsychotics (SGAs) represent a major health concern. A previous study determined that early changes of plasma lipid levels ≥ 5% during the first month of treatment with SGAs predicts further lipid worsening and development of dyslipidemia. This current study aimed to determine the proportion of adolescents with early lipid changes ≥ 5% and who develop dyslipidemia during SGA treatment. Data were obtained from a 1-year longitudinal study ongoing since 2007 including 53 adolescent psychiatric (ICD-10) patients (median age 16.5 years; interquartile range [IQR], 14.8-17.5 years) whose metabolic parameters were monitored prospectively during treatment. Plasma lipid levels (total, low-density lipoprotein, high-density lipoprotein [HDL-C], and non-high-density lipoprotein cholesterol and fasting triglycerides ) were measured at baseline and after 1, 3, and/or 12 months of SGA treatment. Half (n = 26; 49%) the adolescents had an early increase of total cholesterol levels by 5% or more during the first month of treatment, and one-third (n = 8/24; 33%) developed new-onset hypercholesterolemia during the first year of treatment. Hypercholesterolemia developed more frequently in female patients (P = .01) and in patients with an early increase of total cholesterol ≥ 5% (P = .02). Finally, patients whose HDL-C levels decreased by ≥ 5% during the first month of treatment had a larger HDL-C worsening after 3 months of treatment as compared with patients with early decrease of HDL-C by < 5% (P = .02). This study underlines the importance of prospectively monitoring metabolic parameters in adolescents after the introduction of SGAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|